| Old Articles: <Older 5061-5070 Newer> |
|---|
 |
The Motley Fool
August 28, 2008
Brian Orelli |
Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.   |
The Motley Fool
August 27, 2008
Brian Orelli |
Amylin Answers, Investors Panic Amylin Pharmaceuticals' conference call about side effects of its diabetes treatment, Byetta, doesn't have the desired effect. |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
August 27, 2008
Brian Orelli |
Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect. |
Chemistry World
August 26, 2008
Fred Campbell |
High-throughput protein microarrays on the way A new method to rapidly generate protein microarrays has been developed by UK researchers at the University of Manchester. |
Chemistry World
August 26, 2008 |
Photonic crystal drug detective A new high-throughput screening system based on photonic crystals could quickly and cheaply detect molecules that disrupt binding between proteins and DNA. |
The Motley Fool
August 26, 2008
Brian Orelli |
Rapid Exchange of Fire Competitors try to block Abbott's patent extension. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
The Motley Fool
August 26, 2008
Brian Orelli |
Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development. |
The Motley Fool
August 25, 2008
Rich Duprey |
Lipitor Marketing Raises Blood Pressure Pfizer continues affinity-group marketing of its best-selling cholesterol drug Lipitor. |
| <Older 5061-5070 Newer> Return to current articles. |
